ClinicalTrials.gg
Not yet recruitingNCT07567729EEG AnesthesiaUpdated Nov 17, 2026

Effectiveness of Electroencephalography Guided Anesthesia

An interventional study of EEG-guided anesthesia training program for anesthesia providers and EEG-Guided Intervention in Delirium - Postoperative, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 17, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will use brain wave information, known as electroencephalography (EEG), to help guide anesthesia delivery during surgery. It is believed that the use of EEG has the potential to reduce postoperative delirium - a common side effect of general anesthesia. Postoperative delirium is known to cause long lasting cognitive deficits and increase the chance of developing dementia in geriatric patients. This study aims to reduce these risks posed by modern day anesthesia practices through more efficient delivery of anesthesia utilizing brain wave activity information.

02

Conditions studied

  • Delirium - Postoperative

Browse trials for

03

In context

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

This study's planned enrollment of 225 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A Inclusion Criteria:

  • Signed and dated form prior to any study-specific procedures.
  • Willingness and ability to comply with all study procedures and availability for the duration of the study, including all scheduled assessments and follow-up visits.
  • Currently practicing anesthetic provider, defined as either:

    • Attending anesthesiologist, or
    • Certified Registered Nurse Anesthetist (CRNA).
  • Limited prior formal training in EEG interpretation for anesthetic depth, as self-reported by the participant (see Exclusion Criteria for details).
  • Fluent in English, to ensure comprehension of study materials and assessments.
  • Able to access and utilize required technology (e.g., computer or tablet with internet access) for completion of digital modules and online assessments.
  • In good general health and capable of fulfilling clinical duties, as self-reported and confirmed by site investigator review.
  • Willingness to be randomized to any of the study arms and to participate in all assigned educational interventions and assessments.
  • Willingness to adhere to the protocol-specified anesthetic management strategy during the real-case assessments.

Part B Inclusion Criteria:

  • Provides written, signed informed consent prior to the surgical procedure.
  • Is age 60 years or older.
  • Is scheduled to undergo an elective, non-cardiac, non-neurologic surgical procedure expected to last at least two hours.
  • Is planned to receive general anesthesia.
  • Has an (ASA) physical status of I, II, or III.
  • Has intact skin on the forehead suitable for the application of EEG electrodes.

Exclusion criteria

Exclusion Criteria:

Part A Exclusion Criteria:

  • Fellowship training in neuroanesthesia or neurocritical care.
  • Participation in EEG-related research or formal EEG training within the past 12 months.
  • Inability to access or utilize required technology (e.g., computer or tablet with internet access) necessary for completion of digital modules and online assessments.
  • Any condition (physical, psychological, or cognitive) that, in the opinion of the site investigator, would preclude full participation in study activities or completion of the study protocol.
  • Known allergy or sensitivity to materials used in EEG electrodes (e.g., adhesives or gels), if applicable.
  • Non-practicing anesthetic providers (e.g., retired, not currently providing clinical care).

Part B Exclusion Criteria:

  • Is unable to provide legally effective .
  • Is scheduled for emergency, cardiac, or neurologic surgery.
  • Has an (ASA) physical status of IV or greater.
  • Has a pre-existing diagnosis of dementia, significant cognitive impairment, or other major neurologic disease (e.g., epilepsy, Parkinson's disease).
  • Has a known allergy to the adhesives or gels used with EEG electrodes.
  • Has a condition, such as a craniofacial deformity or skin condition on the forehead, that would prevent proper placement or functioning of the EEG monitor.
  • Currently pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Active comparator
    Part A: Anesthesia Providers that Receive Training

    Eligible anesthesia providers that include both anesthesiologists and CRNAs who will receive an EEG-guided anesthesia training program for anesthesia providers.

    Other: EEG-guided anesthesia training program for anesthesia providers

  • No intervention
    Part A: Anesthesia Providers that Do Not Receive Training

    Eligible anesthesia providers that include both anesthesiologists and CRNAs who will did not receive an EEG-guided anesthesia training program for anesthesia providers.

  • Other
    Part B: All Participants Receive the EEG-Guided Intervention

    Part B will be a prospective, single-arm pilot study. As a result, randomization of patients into different groups will not occur, and all patients will receive the EEG-guided intervention. Blinding of the intraoperative clinical team is also not feasible in this case, as providers must be aware of all monitoring tools in use. Instead, this study will mitigate potential for bias by utilizing blinded outcome assessors. Researchers will be kept separate from the intraoperative care team to remain unaware of specific details of the patient's anesthetic course.

    Device: EEG-Guided Intervention

Interventions

  • OtherEEG-guided anesthesia training program for anesthesia providers

    The EEG-guided anesthesia training session for the anesthesia providers will administer simulation-based assessments at baseline, immediately post-intervention, and at one, three, and six month follow-up time points to track provider competency in EEG interpretation and anesthetic titration.

  • DeviceEEG-Guided Intervention

    All surgical patients in Part B of the study will receive EEG-guided anesthesia. EEG data collected from patient participants will be provided as live data during their surgical procedures to the anesthesia provider. Anesthesia providers may use this data to assist their decision-making on anesthetic delivery.

06

What researchers measure

Primary outcomes

  1. Minimum Alveolar Concentration (MAC)

    The primary endpoint is the total intraoperative anesthetic exposure. This will be measured as the time-weighted average of the age-adjusted Minimum Alveolar Concentration (MAC) of volatile anesthetic administered during the maintenance phase of anesthesia. These data will be collected directly from the electronic anesthetic record for each enrolled patient case and will be reviewed and verified by the study team.

    Time frame: Intra-operative phase of care of participant.

Secondary outcomes

  1. 3-Minute Diagnostic Confusion Assessment Method (3D-CAM)

    To gather data for POD progression modeling, patients will be assessed for delirium daily for the first three postoperative days using the 3-Minute Diagnostic Confusion Assessment Method (3D-CAM). These assessments will be performed by trained research staff who are blinded to the patient's treatment group.

    Time frame: Postoperative Days 1 to 3.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 12 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 5, 2026
StartEst.
Jun 1, 2027was Jun 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jan 1, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jun 1, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Jun 1, 2026→Jun 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07567729
Responsible party
David R. Drover (MD, Stanford University) — Principal investigator
First posted
May 5, 2026
Start date
Jun 1, 2027 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Maya Clinical Research Coordinator Associate
Contact
mcaple@stanford.edu
650-724-2620
Ariel Clinical Research Coordinator Associate
Contact
arielkay@stanford.edu
650-724-3021

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion